The collaboration is aimed at creating cloud-based clinical software tools that facilitate comprehensive decision-making for early-stage breast cancer patients
SimBioSys partners with Mayo Clinic to develop AI-powered solutions for cancer patients. (Credit: Solen Feyissa on Unsplash)
SimBioSys has announced a strategic collaboration with Mayo Clinic to advance the development of digital precision medicine solutions for breast cancer patients.
The collaboration is aimed at creating cloud-based clinical software tools that facilitate comprehensive decision-making for early-stage breast cancer patients. This includes personalised surgical planning, treatment strategies, drug selection, and risk assessment.
Mayo Clinic physicians, Dr Judy Boughey, division chair of breast and melanoma surgical oncology, and chair of the Mayo Clinic Comprehensive Cancer Center Breast Cancer Disease Group, alongside Dr Matthew Goetz, enterprise deputy director of translational research and director of Mayo Clinic Breast Cancer SPORE, contribute their expertise as part of the SimBioSys clinical advisory team.
Within the collaboration, SimBioSys has gained access to and analysed data from participants in the Mayo Clinic-led BEAUTY clinical trial (NCT02022202).
Leveraging artificial intelligence (AI) and data science, SimBioSys extracts spatial biophysical insights, aiding clinicians in customising treatment plans for each patient.
SimBioSys conducts simulations using previously acquired data, validating the platform’s predictive accuracy, and engages in in-silico scenario analysis under the guidance of the Mayo Clinic team.
The company has assembled a team comprising scientists, computational biologists, data scientists, and software engineers dedicated to developing TumorSight, a cloud-based platform designated as a software-as-a-medical device.
Currently, under FDA review, the first product on the TumorSight platform uses a patient’s standard-of-care DCE-MRI imaging to construct a personalised 3D digital model of their tumour.
The new tool equips surgical oncologists with 3D spatial visualisations of breast cancer, enhancing surgical planning and patient consultations.
The TumorSight platform presents clear 3D “digital twin” renderings, instantly displaying the tumour within the context of auto-segmented anatomical structures, including skin, vessels, chest, fat, glands, and the heart.
SimBioSys co-founder and CEO Tushar Pandey said: “In the crowded world of genomics, new approaches have many barriers to becoming a new standard of care.
“SimBioSys complements current precision medicine techniques while only relying on readily available and previously acquired datasets such as imaging. We are delighted to collaborate with Mayo Clinic as we bring our innovative technology to patients.”